Former NICE Exec Proposes New UK Fund For ‘High-Impact’ Drugs
Some of the rebates paid by drug companies to the government on their sales of medicines could be placed in a central fund to pay for drugs of “demonstrable benefit,” according to Andrew Dillon.
You may also be interested in...
Plans for a new kind of drug pricing scheme put forward by the UK ABPI are intended to put the life sciences sector “back on the path for future growth,” the association says.
With the clock ticking on UK drug pricing negotiations, it is still unclear whether even high-level terms of a new voluntary deal will be agreed in time.
The pharmaceutical industry says financial uncertainties are a key reason why the English Innovative Medicines Fund (IMF) – offering the potential for time-limited funding for promising non-cancer treatments where benefits are uncertain at launch - has still not been used a year after it was put in place. Industry wants the National Health Service to share the financial risk of taking part in the fund.